Page last updated: 2024-11-05

pamaquine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pamaquine is an antimalarial drug that was first synthesized in 1926. It is a 4-aminoquinoline derivative, similar in structure to chloroquine. Pamaquine is effective against the erythrocytic stage of the Plasmodium parasite, which is responsible for causing malaria. It works by inhibiting the parasite's ability to digest hemoglobin, a vital nutrient for the parasite's survival. Pamaquine is no longer widely used due to its toxicity, but it was historically important in the fight against malaria. It was one of the first effective antimalarial drugs and helped to significantly reduce malaria deaths in the early 20th century. Research on pamaquine continues, particularly in the search for new antimalarial drugs with improved safety profiles and efficacy. Pamaquine has also been investigated for its potential use in the treatment of other diseases, such as cancer and autoimmune disorders. However, these studies are still in early stages.'

pamaquine: structure; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10290
CHEMBL ID472698
CHEBI ID135350
SCHEMBL ID156942
MeSH IDM0045355

Synonyms (50)

Synonym
brn 0027810
n(1),n(1)-diethyl-n(4)-(6-methoxy-8-quinolinyl)-1,4-pentanediamine
8-((4-(diethylamino)-1-methylbutyl)amino)-6-methoxyquinoline
gamefar
1,4-pentanediamine, n1,n1-diethyl-n4-(6-methoxy-8-quinolinyl)-
aminoquin
nsc 167382
quipenyl
beprochine
ccris 6979
quinoline, 8-((4-(diethylamino)-1-methylbutyl)amino)-6-methoxy-
nsc15016
D02547
plasmoquine [veterinary] (tn)
nsc-167382
wln: t66 bnj ho1 jmy1&3n2&2
nsc167382
plasmocide
pamaquine
prequine
praequine
491-92-9
plasmoquine
plasmochin
1, n1,n1-diethyl-n4-(6-methoxy-8-quinolinyl)-
pamaquin
quinoline, 8-[[4-(diethylamino)-1-methylbutyl]amino]-6-methoxy-
CHEBI:135350
1-n,1-n-diethyl-4-n-(6-methoxyquinolin-8-yl)pentane-1,4-diamine
CHEMBL472698
unii-99qvl5kpsu
99qvl5kpsu ,
pamaquine [inn]
4-22-00-05818 (beilstein handbook reference)
SCHEMBL156942
(+/-)-pamaquine
quinoline, 6-methoxy-8-(1-methyl-4-diethylamino)butylamino-
pamaquine [mi]
pamaquine, (+/-)-
plasmoquin
AC6214
8-[[4-(diethylamino)-1-methylbutyl]amino]-6-methoxy-quinoline
n1,n1-diethyl-n4-(6-methoxy-8-quinolyl)pentane-1,4-diamine
Q3391724
mfcd00024026
SY248279
n1,n1-diethyl-n4-(6-methoxy-8-quinolyl)-1,4-pentanediamine
n1,n1-diethyl-n4-(6-methoxyquinolin-8-yl)pentane-1,4-diamine
FT-0775257
DTXSID90862331

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The risk of drug-induced G6PD deficiency-related hemolysis depends on a number of factors including the G6PD variant, the drug and drug dosage schedule, patient status, and disease factors."( Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development.
Beutler, E; Duparc, S, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aminoquinolineAny member of the class of quinolines in which the quinoline skeleton is substituted by one or more amino or substituted-amino groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1849699Drug elimination in human urine assessed as unchanged fraction2021European journal of medicinal chemistry, Jan-15, Volume: 210An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (75)

TimeframeStudies, This Drug (%)All Drugs %
pre-199061 (81.33)18.7374
1990's4 (5.33)18.2507
2000's6 (8.00)29.6817
2010's3 (4.00)24.3611
2020's1 (1.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.47 (24.57)
Research Supply Index4.38 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index68.16 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (48.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.53%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other77 (97.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]